MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe.
Flawless balance sheet with solid track record.
Share Price & News
How has MeVis Medical Solutions's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: M3V has not had significant price volatility in the past 3 months.
7 Day Return
DE Healthcare Services
1 Year Return
DE Healthcare Services
Return vs Industry: M3V underperformed the German Healthcare Services industry which returned 27.5% over the past year.
Return vs Market: M3V underperformed the German Market which returned 10.4% over the past year.
Price Volatility Vs. Market
How volatile is MeVis Medical Solutions's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StDo You Like MeVis Medical Solutions AG (ETR:M3V) At This P/E Ratio?
3 weeks ago | Simply Wall StWhat MeVis Medical Solutions AG's (ETR:M3V) ROE Can Tell Us
1 month ago | Simply Wall StHow Much Did MeVis Medical Solutions AG's (ETR:M3V) CEO Pocket Last Year?
Is MeVis Medical Solutions undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: M3V (€29.8) is trading above our estimate of fair value (€15.33)
Significantly Below Fair Value: M3V is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: M3V is good value based on its PE Ratio (6.9x) compared to the Healthcare Services industry average (11.5x).
PE vs Market: M3V is good value based on its PE Ratio (6.9x) compared to the German market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: M3V's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: M3V is good value based on its PB Ratio (1.4x) compared to the DE Healthcare Services industry average (2.3x).
How is MeVis Medical Solutions forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: M3V's earnings are forecast to decline over the next 3 years (-31.1% per year).
Earnings vs Market: M3V's earnings are forecast to decline over the next 3 years (-31.1% per year).
High Growth Earnings: M3V's earnings are forecast to decline over the next 3 years.
Revenue vs Market: M3V's revenue is expected to decline over the next 3 years (-12.5% per year).
High Growth Revenue: M3V's revenue is forecast to decline over the next 3 years (-12.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: M3V's Return on Equity is forecast to be low in 3 years time (8.9%).
How has MeVis Medical Solutions performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: M3V has high quality earnings.
Growing Profit Margin: M3V's current net profit margins (45.4%) are higher than last year (41.1%).
Past Earnings Growth Analysis
Earnings Trend: M3V's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: M3V's earnings growth over the past year (15.3%) exceeds its 5-year average (13.4% per year).
Earnings vs Industry: M3V earnings growth over the past year (15.3%) underperformed the Healthcare Services industry 27.6%.
Return on Equity
High ROE: M3V's Return on Equity (20.7%) is considered high.
Return on Assets
Return on Capital Employed
How is MeVis Medical Solutions's financial position?
Financial Position Analysis
Short Term Liabilities: M3V's short term assets (€10.5M) exceeds its short term liabilities (€3.6M)
Long Term Liabilities: M3V's short term assets (€10.5M) exceeds its long term liabilities (327.0K)
Debt to Equity History and Analysis
Debt Level: M3V is debt free.
Reducing Debt: M3V has not had any debt for past 5 years.
Debt Coverage: M3V has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: M3V has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: M3V has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if M3V's debt is covered by short term assets.
What is MeVis Medical Solutions's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate M3V's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate M3V's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if M3V's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if M3V's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: M3V is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of M3V's dividend in 3 years as they are not forecast to pay a notable one for the German market.
What is the CEO of MeVis Medical Solutions's salary, the management and board of directors tenure and is there insider trading?
Average board tenure
Marcus Kirchhoff (50yo)
Mr. Marcus Kirchhoff has been the Chief Executive Officer, Chairman of the Board and Member of the Executive Board at MeVis Medical Solutions AG since March 1, 2012. Mr. Kirchhoff serves as Vice President ...
CEO Compensation Analysis
Compensation vs Market: Marcus's total compensation ($USD275.35K) is about average for companies of similar size in the German market ($USD215.15K).
Compensation vs Earnings: Marcus's compensation has been consistent with company performance over the past year.
Board Age and Tenure
Experienced Board: M3V's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Marcus Kirchhoff (50yo)
Chairman of the Executive Board & CEO
- Tenure: 7.7yrs
- Compensation: €248.83k
Clarence Verhoef (64yo)
Deputy Chairman of Supervisory Board
- Tenure: 2.7yrs
Member of the Supervisory Board
- Tenure: 2.7yrs
Kim Honeysett (47yo)
Chairperson of Supervisory Board
- Tenure: 2.7yrs
MeVis Medical Solutions AG's company bio, employee growth, exchange listings and data sources
- Name: MeVis Medical Solutions AG
- Ticker: M3V
- Exchange: XTRA
- Founded: 1992
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: €54.236m
- Shares outstanding: 1.82m
- Website: https://www.mevis.de
Number of Employees
- MeVis Medical Solutions AG
- Caroline-Herschel-Strasse 1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|M3V||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Nov 2007|
|M3V||XTRA (XETRA Trading Platform)||Yes||Registered Shares||DE||EUR||Nov 2007|
|0HI7||LSE (London Stock Exchange)||Yes||Registered Shares||GB||EUR||Nov 2007|
MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United St ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/11/20 21:06|
|End of Day Share Price||2019/11/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.